Skip to main content
Premium Trial:

Request an Annual Quote

Caris Life Sciences, Juniper Biologics Expand Solid Tumor Profiling Distribution Deal

NEW YORK – Singapore-based Juniper Biologics announced Monday that it obtained the exclusive distribution rights for Caris Life Sciences' molecular profiling services throughout the Middle East and Africa.

The agreement expands on last year's deal that granted Juniper exclusive distribution rights covering Southeast Asia.

Services covered by the agreement include whole-exome and transcriptome sequencing to guide the use of molecularly targeted therapies. Financial details were not disclosed.

"Our exclusive partnership with Caris Life Sciences to distribute this service in the Middle East and Africa will significantly empower healthcare professionals to make informed decisions for their patients," Raman Singh, founder and CEO of Juniper, said in a statement. "This service enables oncologists to recommend highly personalized treatments that specifically target a patient's cancer, thereby improving and expanding their care options. This targeted approach offers patients, particularly those with rare or aggressive cancers, an improved quality of life."